Research programme: inflammation therapy - Nycomed/Pharmacopeia Drug Discovery
Latest Information Update: 05 Jun 2007
At a glance
- Originator Nycomed; Pharmacopeia Drug Discovery
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 31 Dec 2003 Preclinical trials in Inflammation in Germany (unspecified route)